49.25

1.27% 0.62

After Hours: 49.25

Sanofi Adr (SNY)

Overview News Price History Option Chain Why SNY Down? Discussions Forecast Dividend History

Sanofi Adr stock is traded at $49.25, with a volume of 5.26M. It is up +1.27% in the last 24 hours and up +0.45% over the past month. Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

Previous Close:

$48.63

Open:

$48.49

24h Volume:

5.26M

Relative Volume:

1.75

Market Cap:

$118.95B

Revenue:

$49.41B

Net Income/Loss:

$5.59B

P/E Ratio:

19.10

EPS:

2.5789

Net Cash Flow:

$12.54B

1W Performance:

+2.43%

1M Performance:

+0.45%

6M Performance:

+4.32%

1Y Performance:

-8.63%

1-Day Range:

$48.15

$49.42

1-Week Range:

$47.35

$49.42

52-Week Range:

$44.62

$60.12

Sanofi Adr Stock (SNY) Company Profile

Name

Sanofi Adr

Sector

Healthcare (1108)

Industry

Drug Manufacturers - General (20)

Phone

Address

Employee

82,878

Twitter

@sanofi

Next Earnings Date

2026-01-29

Latest SEC Filings

SNY's Discussions on Twitter

Compare SNY vs LLY, JNJ, ABBV, AZN, NVS

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SNY Sanofi Adr	49.25	117.46B	49.41B	5.59B	12.54B	2.5789
LLY Lilly Eli Co	1,015.21	917.39B	65.18B	20.64B	6.44B	22.96
JNJ Johnson Johnson	240.86	574.26B	94.19B	26.80B	20.46B	11.05
ABBV Abbvie Inc	220.89	393.14B	61.16B	4.20B	19.68B	2.3671
AZN Astrazeneca Plc	204.76	299.82B	58.07B	9.40B	9.87B	3.0115
NVS Novartis Ag Adr	160.06	301.87B	54.72B	14.02B	15.32B	7.1855

Sanofi Adr Stock (SNY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-27-26	Initiated	Citigroup	Neutral
Jan-16-26	Downgrade	UBS	Buy → Neutral
Jan-06-26	Downgrade	Barclays	Overweight → Equal Weight
Dec-09-25	Downgrade	Guggenheim	Buy → Neutral
Dec-08-25	Downgrade	JP Morgan	Overweight → Neutral
Sep-08-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Sep-02-25	Upgrade	Deutsche Bank	Hold → Buy
Aug-08-25	Upgrade	JP Morgan	Neutral → Overweight
Apr-15-25	Initiated	Exane BNP Paribas	Outperform
Mar-21-25	Initiated	Goldman	Neutral
Jan-30-25	Upgrade	Deutsche Bank	Sell → Hold
Jul-26-24	Reiterated	Argus	Buy
Jan-23-24	Initiated	Morgan Stanley	Equal-Weight
Jan-16-24	Resumed	UBS	Buy
Dec-05-23	Downgrade	JP Morgan	Overweight → Neutral
Oct-30-23	Downgrade	Stifel	Buy → Hold
Sep-06-23	Upgrade	Berenberg	Hold → Buy
Jul-14-23	Initiated	HSBC Securities	Buy
Apr-28-23	Downgrade	Deutsche Bank	Hold → Sell
Mar-27-23	Upgrade	Barclays	Equal Weight → Overweight
Dec-13-22	Resumed	Morgan Stanley	Overweight
Aug-12-22	Upgrade	Deutsche Bank	Sell → Hold
Aug-09-22	Downgrade	UBS	Buy → Neutral
May-23-22	Initiated	SVB Leerink	Outperform
Sep-27-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Jan-15-21	Initiated	Deutsche Bank	Sell
Sep-29-20	Initiated	Berenberg	Hold
Mar-17-20	Upgrade	Barclays	Underweight → Equal Weight
Mar-11-20	Upgrade	Goldman	Neutral → Buy
Feb-11-20	Initiated	SVB Leerink	Mkt Perform
Jan-06-20	Upgrade	JP Morgan	Neutral → Overweight
Sep-23-19	Upgrade	Guggenheim	Neutral → Buy
Sep-20-19	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Sep-03-19	Initiated	Bernstein	Outperform
Aug-14-19	Upgrade	UBS	Neutral → Buy
Dec-11-18	Upgrade	Jefferies	Hold → Buy
Nov-01-18	Upgrade	Barclays	Underweight → Equal Weight
Oct-09-18	Initiated	Guggenheim	Neutral
Sep-10-18	Upgrade	BofA/Merrill	Neutral → Buy
Aug-10-18	Upgrade	Citigroup	Neutral → Buy
Mar-23-18	Upgrade	Liberum	Hold → Buy
Jan-23-18	Downgrade	Barclays	Equal Weight → Underweight
Dec-06-17	Downgrade	BofA/Merrill	Buy → Neutral
Dec-01-17	Downgrade	Morgan Stanley	Overweight → Underweight
Nov-15-17	Upgrade	Barclays	Underweight → Equal Weight
Aug-30-17	Upgrade	HSBC Securities	Reduce → Hold